Heather Cwach, MD
Neurology · Rapid City, SDNPI 1255481420
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Jazz Pharmaceuticals Inc. at 25.1% of the total. Reporting peaked in 2022 at $788 and has fallen 68.3% since, to $250 in 2024.
Across 62 payments — averaging $29.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Jazz Pharmaceuticals Inc.$452
- AstraZeneca$256
- SK Life Science, Inc.$198
- Amneal Pharmaceuticals LLC$189
- Harmony Biosciences LLC$134
- AbbVie$113
- plus $461 from 15 others
What the payments were for
- Food & beverage$1,802100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Jazz Pharmaceuticals Inc. | 4 | $452 |
| AstraZeneca | 10 | $256 |
| SK Life Science, Inc. | 3 | $198 |
| Amneal Pharmaceuticals LLC | 9 | $189 |
| Harmony Biosciences LLC | 2 | $134 |
| AbbVie(2 entities) | 7 | $113 |
| UCB, Inc. | 4 | $85 |
| Amgen | 5 | $61 |
| CSL Behring | 2 | $48 |
| Acadia Pharmaceuticals Inc | 3 | $45 |
| Livanova USA, Inc. | 1 | $31 |
| Biogen | 2 | $30 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Novartis | 1 | $23 |
| Eisai Inc. | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| Upsher-smith Laboratories LLC | 1 | $16 |
| Tanabe Pharma America, Inc. | 1 | $14 |
| Teva Pharmaceuticals USA, Inc. | 1 | $14 |
| Supernus Pharmaceuticals, Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,802 in reported general payments places this provider in the 65th percentile of 49 neurology providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Levetiracetam | 197 | $5,390 |
| Lacosamide | 32 | $3,839 |
| Oxcarbazepine | 44 | $3,747 |
| Carbamazepine ErCarbamazepine | 16 | $2,528 |
| Lamotrigine | 178 | $2,480 |
| Divalproex Sodium | 51 | $1,991 |
| Divalproex Sodium ErDivalproex Sodium | 16 | $1,891 |
| Carbamazepine | 19 | $1,445 |
| Topiramate | 54 | $1,283 |
| Gabapentin | 12 | $877 |
| Zonisamide | 32 | $864 |
| Clonazepam | 30 | $115 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Upsher-smith Laboratories LLCTopiramate | $16 | $1,28354 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 49 neurology providers in South Dakota.
Other neurology in Rapid City
- Jennifer KrugerRapid City$19K
- Mohamadmostafa JahansouzRapid City$3K
- Lee McCraneyRapid City$2K
- Barbara MerrimanRapid City$2K
- Brian TschidaRapid City$1K
- Robert FinleyRapid City$732
- Eunhye OakRapid City$429
- Steven HataRapid City$407
- Matthew SimmonsRapid City$250
- Robert MaclachlanRapid City$163
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.